Changes in Hong Kong stocks | Tongyuankang Pharmaceutical-B (02410) rose more than 8%. The first batch of Kadasha will complete production and is expected to be officially commercialized in China by the end of November

The Zhitong Finance App learned that Tongyuankang Pharmaceutical-B (02410) rose more than 8%. As of press release, it had risen 8.01% to HK$4.18, with a turnover of HK$821,700.

According to the news, Tongyuankang Pharmaceutical-B issued an announcement. As announced by the company on August 27, 2026, the new drug Kadasha (TY-9591) has been approved by the China National Drug Administration for first-line treatment of adult patients with epidermal growth factor receptor (EGFR) exon 19 deficiency (19DEL) or exon 21 (L858R) replacement mutations, accompanied by central nervous system (CNS) metastases.

Production of the first batch of Kadasha (TY-9591) is expected to be completed on November 18, 2026. It is expected that at the end of November 2026, the first batch of Kadasha (TY-9591) products will be officially delivered to Qilu's designated first-level distributors through commercial channels. Qilu is expected to launch an academic promotion campaign on November 13, 2026. This move marks the official launch of Kadasha (TY-9591) commercial sales and prescription business in China. Looking ahead, the company will continue to cooperate with Qilu Pharmaceutical (Hainan) Co., Ltd. (Qilu) to commercialize Kadasha (TY-9591) in accordance with the licensing and cooperation agreements and supply and commercialization agreements outlined in the company's announcements dated July 21, 2026 and November 11, 2026.